Skip to main navigation
Skip to search
Skip to main content
Bar-Ilan University Home
Help & FAQ
Home
Researchers
Organisations
Research output
Prizes
Student theses
Activities
Press/Media
Datasets
Equipment
Search by expertise, name or affiliation
Ezetimibe added to statin therapy after acute coronary syndromes
IMPROVE-IT Investigators
Bar-Ilan University - Azrieli Faculty of Medicine
Harvard University
Duke University
University of Montreal
Vivantes Neukölln Medical Center
Carmel Medical Center
Canisius Wilhelmina Hospital
Leiden University
University of Pavia
Cardinal Stefan Wyszynski Institute of Cardiology
Merck
Research output
:
Contribution to journal
›
Article
›
peer-review
3392
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Ezetimibe added to statin therapy after acute coronary syndromes'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Acute Coronary Syndrome
100%
Statin Therapy
100%
Ezetimibe
100%
Simvastatin
100%
Low-density Lipoprotein Cholesterol Level
57%
Monotherapy
42%
Lipid-lowering Therapy
28%
Adverse Effects
14%
Confidence Interval
14%
Hazard Ratio
14%
Placebo
14%
Nonfatal Myocardial Infarction
14%
Cardiovascular Mortality
14%
Cardiovascular Risk
14%
Non-statins
14%
Stable Angina
14%
Median Time
14%
Cardiovascular Events
14%
Cardiovascular Outcomes
14%
Rehospitalization
14%
Low-density Lipoprotein Cholesterol (LDL-C)
14%
Nonfatal Stroke
14%
Coronary Revascularization
14%
Double-blind Randomized Trial
14%
Kaplan-Meier
14%
Absolute Risk Difference
14%
Intestinal Cholesterol Absorption
14%
Time-weighted Average
14%
Gallbladder
14%
Event Rate
14%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Coronary Syndrome
100%
Ezetimibe
100%
Statin (Protein)
100%
Simvastatin
100%
Low Density Lipoprotein Cholesterol
71%
Monotherapy
42%
Placebo
14%
Malignant Neoplasm
14%
Heart Infarction
14%
Adverse Event
14%
Unstable Angina Pectoris
14%